Supernus Pharmaceuticals Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 12 trades in Supernus Pharmaceuticals Inc (NASDAQ: SUPN) since 2017, across 3 members, worth an estimated $120.50K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 9 buys against 3 sells, a modestly buy-led skew, with Democratic members responsible for 75% of the trades and Republican members 25%. The most recent disclosure shown was filed April 2026, and Gilbert Cisneros has filed the most SUPN transactions among those shown, with 3. One notable disclosed move was a purchase by Gilbert Cisneros on March 3, 2026, down 16.9% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Supernus Pharmaceuticals Inc's current Quantellect Tide Score is 57 out of 100 (High Tide), Top 37% of universe (3876); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Supernus Pharmaceuticals Inc (SUPN) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Supernus Pharmaceuticals congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Gilbert Cisneros House | Apr 7, 2026 | Mar 3, 2026 | 35 days | BUY |  $1,001 - $15,000 | -16.86% | Self | |
Gilbert Cisneros House | Jan 12, 2026 | Dec 11, 2025 | 32 days | BUY | $1,001 - $15,000 | -2.47% | Self | |
Gilbert Cisneros House | Nov 18, 2025 | Oct 9, 2025 | 40 days | SELL | $1,001 - $15,000 | -8.38% | Self |
Supernus Pharmaceuticals (SUPN) congressional trading FAQ
Can members of Congress legally trade Supernus Pharmaceuticals (SUPN) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Supernus Pharmaceuticals (SUPN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Supernus Pharmaceuticals (SUPN) trades public?
Yes. Every congressional trade in Supernus Pharmaceuticals (SUPN) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Supernus Pharmaceuticals (SUPN)?
Members of Congress have disclosed 12 trades in Supernus Pharmaceuticals (SUPN) worth $120.50K across 3 members, according to public STOCK Act filings.
Which members of Congress have traded Supernus Pharmaceuticals (SUPN)?
Recent and active filers of Supernus Pharmaceuticals (SUPN) disclosures include Gilbert Cisneros. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Supernus Pharmaceuticals (SUPN) more?
Across disclosed Supernus Pharmaceuticals (SUPN) trades, 75% were by Democrats and 25% by Republicans, led by Democrats (75%).
What is the most recent congressional Supernus Pharmaceuticals (SUPN) trade?
The most recent disclosed Supernus Pharmaceuticals (SUPN) trade was a purchase by Gilbert Cisneros, filed Apr 6, 2026.
What is Supernus Pharmaceuticals (SUPN)'s Tide Score?
Supernus Pharmaceuticals (SUPN) has a Quantellect Tide Score of 57 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewSupernus Pharmaceuticals (SUPN) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.